Jeito Money co-leads $110 Million Series A Funding in Neogene Therapeutics

Rafaèle Tordjman Launches JEITO CAPITAL, a New Private Equity Company  Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of JEITO  I at €200 Million

Jeito Cash co-qualified prospects $110 Million Sequence A Financing in Neogene Therapeutics

  • Neogene gets to be Jeito Capital’s first expenditure following the fund I launch in January 2020
  • Round co-led by Jeito Cash along with EcoR1 Capital and Syncona with help from Neogene Therapeutics’ strategic seed traders Vida Ventures, TPG and Two River
  • Neogene Therapeutics is targeted on building a new course of thoroughly personalised neo-antigen T mobile therapies to deal with a range of cancers, with a target on good tumors

Paris, France, 14 September 2020 – Jeito Cash (“Jeito”), a promptly rising independent trader focused to biotech and biopharma, now declared that it has co-led a $110 million Series A financing in Neogene Therapeutics, Inc. (“Neogene”), a pre-scientific phase biotechnology company revolutionary a new course of entirely individualized neo-antigen T cell therapies to handle cancer. The financing was co-led by Jeito along with new buyers EcoR1 Money and Syncona with support from Neogene’s strategic seed investors Vida Ventures, TPG and Two River.

Neogene has developed a proprietary technological innovation platform that is capable to establish and isolate precise T mobile receptor (TCR) genes from program tumor samples working with condition-of-the-art artificial biology resources. Employing this point out-of-the-artwork artificial biology, Neogene’s platform selects recognized TCRs specific to mutated proteins found in a patient’s cancer cells (neo-antigens) with substantial sensitivity, specificity and at scale. The isolated TCR genes are subsequently engineered into T cells of cancer sufferers to present huge quantities of potent and focused T cells for remedy.

Neogene has now accomplished evidence-of-principle for its neo-antigen technologies system and the Sequence A funding will help the Company to even further acquire its technology and progress in direction of medical phase. The money will also be utilized to increase the Company’s offices in Amsterdam, New York and Santa Monica.

Rafaèle Tordjman, Founder and CEO at Jeito, said: “We are exceptionally happy to have manufactured our initial investment decision in accordance to approach and in these types of a high-excellent organization. Neogene’s technique perfectly aligns with Jeito’s mission to aid new and founded business owners aspiring to assist sufferers in need by pioneering novel, ground-breaking medications that rethink standard approaches. With the depth of expertise of Neogene’s management workforce, the good quality of its science, and its powerful new and present investor base we believe that that Neogene has substantial potential to completely transform cancer remedy for clients all-around the planet. 

“Despite the ongoing COVID-19 pandemic, we have been inspired by our robust deal circulation in Europe and we keep on being on track to meet our targets. We search forward to asserting further more investments in the in the vicinity of long run as we go on to discover possibilities to spend in floor-breaking health care innovation in Europe and further than.”

Dr. Carsten Linnemann, CEO at Neogene, claimed: “Neogene is fully commited to forging a new path for entirely personalised remedy solutions for most cancers individuals and we are delighted to welcome Jeito Money as a new trader alongside EcoR1 Funds and Syncona. Attracting traders of these types of a substantial caliber is a further more validation of our technological innovation and tactic to provide personalised engineered T mobile therapies to clients.”


About Jeito Capital
Jeito Funds is an global expense firm with a client benefit pushed solution that focuses each on financing floor-breaking health care innovation and endorsing beneficial societal impression. Jeito has a distinctive, long-term expense approach, with the intention of providing continuity from scientific progress to marketplace access for breakthrough medication with validated proofs of notion. This continuity is expressed both equally in the aid supplied to business owners by the Jeito Cash workforce and by the expenditure of major cash to be certain the advancement of businesses, the acceleration toward commercialization and more quickly accessibility to these key innovations.  Jeito Capital is based mostly in Paris with a presence in Europe and the United States.  

About Neogene Therapeutics
Neogene Therapeutics, Inc. is a pre-scientific stage biotechnology corporation revolutionary improvement of next-technology, entirely personalised engineered T cells therapies for a broad spectrum of cancers. The Company’s engineered T cells target mutated proteins observed in cancer cells owing to most cancers-connected DNA mutations, or neo-antigens, that render tumor cells susceptible to detection by T cells. Neogene’s proprietary technological innovation platform aims to discover TCR genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel method intends to supply a tailored established of TCR genes for just about every particular person individual, which will be engineered into affected person-derived T cells directing them to neo-antigens in tumor cells, with the purpose of providing a absolutely customized engineered T mobile remedy for most cancers.

Neogene was founded in 2018 by a workforce of environment-course cell treatment specialists to advance the advancement of neo-antigen T mobile therapies. Carsten Linnemann, Ph.D., Chief Government Officer of Neogene, and Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute, Oncode Institute and 2020 recipient of the Dutch Study Council’s Stevin Award co-started the Organization with unique investments by cell treatment industry veterans Arie Belldegrun, M.D. FACS, founder of Kite Pharma, Inc. and Co-Founder and Govt Chairman of Allogene Therapeutics, Inc. and David Chang, M.D., Ph.D., Co-Founder, President and Main Govt Officer of Allogene. Dr. Linnemann and Dr. Schumacher beforehand co-founded T-Mobile Manufacturing facility B.V., a company acquired by Kite Pharma in 2015. Dr. Schumacher, an internationally top immunologist in the regions of neo-antigen biology and T cell engineering, developed the seminal ideas of Neogene’s proprietary technological know-how. For additional info, you should visit, and observe @Neogene Therapeutics on LinkedIn.

For far more info you should get hold of:

Jeito Funds

Rafaèle Tordjman, Founder and CEO

get hold [email protected]

  Consilium Strategic Communications

Mary-Jane Elliott / Melissa Gardiner / Kris Lam

[email protected]


Tel: +33 6 03 35 47 57



Tel: +44 () 20 3709 5700